A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Breast Cancer
Unknown Primary
18 Years and older, Male and Female
PUMA-ALI-1201 (primary)
NCI-2024-06850
2024-511497-79-00
Summary
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib
administered in combination with endocrine therapy in participants with
pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following
progression on or after at least two prior lines of endocrine therapy in the recurrent or
metastatic setting. This study is intended to evaluate the optimal alisertib dose
administered in combination with the selected endocrine therapy. The study is also
planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in
combination with endocrine and to identify the biomarker-defined subgroup(s) that may
benefit most from combined alisertib and endocrine therapy.
Eligibility
- Aged =18 years at signing of informed consent.
- Pathology-confirmed diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to curative therapy.
- Progression on or after treatment with at least two prior lines of endocrine therapy in the recurrent or metastatic setting. a. If metastatic disease recurrence occurs during or within six months of discontinuing adjuvant endocrine therapy, then that endocrine therapy will count as one line of prior therapy.
- Participants must have received a CDK4/6i in combination with endocrine therapy in the recurrent or metastatic setting.
- HR-positive and HER2-negative tumor status reported per local laboratory testing. HR and HER2 testing must be performed consistent with current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) or European Society of Medical Oncology (ESMO) guidelines:
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.